Evidence map›Paper›PMID 34302290›Full record

ArticlePaediatric drugs2021

Pharmacokinetics of Ceftazidime in Children and Adolescents with Obesity.

Anil R Maharaj, Huali Wu, Kanecia O Zimmerman, William J Muller, Janice E Sullivan, Catherine M T Sherwin, Julie Autmizguine, Mobeen H Rathore, Chi D Hornik, Amira Al-Uzri and 4 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Paediatric drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01431326 (Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01431326 completednot on this map

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

TypeobservationalSponsorDaniel BenjaminRan2011 to 2019Enrolled3,520ConditionsAdenovirus, Anesthesia, Anxiety, AnxiolysisArmsThe POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anil R MaharajFaculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada.
Huali WuDuke Clinical Research Institute, Duke University School of Medicine, 300 West Morgan Street, Box 3850, Durham, NC, 27701, USA.
Kanecia O ZimmermanDuke Clinical Research Institute, Duke University School of Medicine, 300 West Morgan Street, Box 3850, Durham, NC, 27701, USA.
William J MullerDepartment of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University, Chicago, IL, USA.
Janice E SullivanDepartment of Pediatrics, University of Louisville and Norton Children's Hospital, Louisville, KY, USA.
Catherine M T SherwinDepartment of Pediatrics, Wright State University Boonshoft School of Medicine, Dayton Children's Hospital, Dayton, OH, USA.
Julie AutmizguineDepartment of Pharmacology and Pediatrics, Research Center, CHU Sainte-Justine, Montreal, QC, Canada.
Mobeen H RathoreDivision of Pediatric Infectious Diseases and Immunology, University of Florida Center for HIV/AIDS Research, Education, and Service, Wolfson Children's Hospital, Jacksonville, FL, USA.
Chi D HornikDuke Clinical Research Institute, Duke University School of Medicine, 300 West Morgan Street, Box 3850, Durham, NC, 27701, USA.
Amira Al-UzriDepartment of Pediatrics, Oregon Health and Science University, Portland, OR, USA.
Elizabeth H PayneThe Emmes Company, LLC, Rockville, MD, USA.
Daniel K BenjaminDuke Clinical Research Institute, Duke University School of Medicine, 300 West Morgan Street, Box 3850, Durham, NC, 27701, USA.
Christoph P HornikDuke Clinical Research Institute, Duke University School of Medicine, 300 West Morgan Street, Box 3850, Durham, NC, 27701, USA. christoph.hornik@duke.edu.
Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee

Funding

COVID-19 Supplement - Center for Innovative TRIals in ChilDrEN and AdulTs (TRIDENT)U24TR001608 · NCATS · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K., BERNARD, GORDON RAPHAEL · 2016 to 2022
$177.0M
University of Utah Center for Clinical and Translational ScienceUL1TR001067 · NCATS · UNIVERSITY OF UTAH · PI DERE, WILLARD H., HESS, RACHEL · 2013 to 2017
$19.8M
University of Louisville Center for Integrative Environmental Health SciencesP30ES030283 · NIEHS · UNIVERSITY OF LOUISVILLE · PI Amanda Jo LeBlanc · 2020 to 2026
$10.0M
Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary DysplasiaR33HL147833 · NHLBI · DUKE UNIVERSITY · PI HORNIK, CHRISTOPH, LAUGHON, MATTHEW · 2021 to 2023
$6.8M
Duke CTSA (Composite)KL2TR001115 · NCATS · DUKE UNIVERSITY · PI BOULWARE, LEIGH E, KRAFT, MONICA · 2013 to 2017
$5.1M
The Kentucky Pediatric Clinical Trials Rural/Urban PartnershipUG1OD024954 · OD · UNIVERSITY OF LOUISVILLE · PI Lori Ann Devlin-Phinney, Sara E Watson · 2016 to 2026
$4.3M
Physiologically-Based Pharmacokinetic Models for Optimal Drug Dosing in ChildrenR01HD076676 · NICHD · DUKE UNIVERSITY · PI COHEN-WOLKOWIEZ, MICHAEL · 2014 to 2017
$2.6M
Investigating polypharmacy-related adverse events in critically ill children using electronic health records and simulated drug levelsK23HD091398 · NICHD · DUKE UNIVERSITY · PI ZIMMERMAN, KANECIA OBIE · 2017 to 2020
$629k
Pediatric Critical Care Research Landscape - A National Expert ConferenceR13HD102136 · NICHD · DUKE UNIVERSITY · PI HORNIK, CHRISTOPH, ZIMMERMAN, KANECIA OBIE · 2020 to 2020
$60k
The Kentucky Pediatric Clinical Trials Rural/Urban PartnershipUG1HD090904 · NICHD · UNIVERSITY OF LOUISVILLE · PI SULLIVAN, JANICE E, WATSON, SARA E · 2016 to 2016
$8k
FDA HHS R01 FD006099FDA HHS U18 FD006298FDA HHS UG3 FD006797FDA HHS UH3 FD006797NCATS NIH HHS KL2 TR001115NCATS NIH HHS U24 TR001608NCATS NIH HHS UL1 TR001067NHLBI NIH HHS R33 HL147833NICHD NIH HHS HHSN267200700051CNICHD NIH HHS HHSN275201000003CNICHD NIH HHS HHSN275201000003INICHD NIH HHS HHSN275201800003INICHD NIH HHS K23 HD091398NICHD NIH HHS R01 HD076676NICHD NIH HHS R13 HD102136NICHD NIH HHS UG1 HD090904NIEHS NIH HHS P30 ES030283NIH HHS UG1 OD024954
6 · The paper itself

Abstract

purposeThe aim of this study was to evaluate ceftazidime pharmacokinetics (PK) in a cohort that includes a predominate number of children and adolescents with obesity and assess the efficacy of competing dosing strategies.

methodsA population PK model was developed using opportunistically collected plasma samples. For each dosing strategy, model-based probability of target attainment (PTA) estimates were computed for study participants using empirical Bayes estimates. In addition, the effects of body size and renal function on PTA were evaluated using stochastic model simulations with virtually generated subjects.

resultsTwenty-nine participants, 24 of whom were obese, contributed data towards the analysis. The median (range) age, body weight, and body mass index of participants were 12.2 years (2.3-20.6), 59.2 kg (8.4-121), and 25.2 kg/m

conclusionOur analysis suggests administration of 40 mg/kg IV q6h (max 8 g/day) maximizes PTA in children and adolescents with obesity and GFR ≥ 80 mL/min/1.73 m

trial registrationClinicaltrials.gov Identifier: NCT01431326.

Indexed as

AdolescentAnti-Bacterial AgentsBayes TheoremCeftazidimeChildChild, PreschoolFemaleHumansMaleMicrobial Sensitivity TestsMonte Carlo MethodPediatric ObesityYoung AdultAnti-Bacterial AgentsCeftazidime

Identifiers

PMID34302290
PMCPMC9706343

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.